Biogen's Stock Surge: A Deep Dive

Biogen, a leading biotech firm, has seen its stock soar, reaching a 52-week high and outpacing the Dow Jones. The companys third-quarter results, showing a 67% growth in Alzheimers and rare disease products, have contributed to a 14% year-over-year increase in stock value. Analysts Moderate Buy consensus and the stocks trading above its average price target suggest continued optimism for Biogens future performance.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.